Brokerages Set Benitec Biopharma Inc. (NASDAQ:BNTC) PT at $24.43

Benitec Biopharma Inc. (NASDAQ:BNTC) has been assigned a consensus rating of “Buy” from the nine analysts that are presently covering the firm, MarketBeat Ratings reports. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $24.43.

Several equities research analysts have recently issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and set a $28.00 price objective on shares of Benitec Biopharma in a research report on Friday, February 21st. Baird R W upgraded Benitec Biopharma to a “strong-buy” rating in a research note on Thursday, December 12th. Guggenheim reaffirmed a “buy” rating and set a $17.00 price objective on shares of Benitec Biopharma in a research report on Tuesday, December 3rd. Finally, Robert W. Baird started coverage on Benitec Biopharma in a report on Friday, December 13th. They issued an “outperform” rating and a $30.00 price objective on the stock.

Benitec Biopharma Stock Performance

Shares of BNTC opened at $15.34 on Friday. Benitec Biopharma has a 1 year low of $4.75 and a 1 year high of $15.97. The stock has a market capitalization of $359.74 million, a PE ratio of -10.16 and a beta of 0.92. The stock has a 50-day simple moving average of $11.51 and a 200-day simple moving average of $10.77.

Benitec Biopharma (NASDAQ:BNTC) last issued its quarterly earnings results on Friday, February 14th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.19. Analysts predict that Benitec Biopharma will post -1.48 EPS for the current year.

Insiders Place Their Bets

In other Benitec Biopharma news, Director Suvretta Capital Management, L bought 27,502 shares of the business’s stock in a transaction dated Monday, December 23rd. The shares were acquired at an average cost of $10.98 per share, with a total value of $301,971.96. Following the acquisition, the director now directly owns 7,981,725 shares of the company’s stock, valued at $87,639,340.50. The trade was a 0.35 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 1.30% of the company’s stock.

Institutional Trading of Benitec Biopharma

Large investors have recently bought and sold shares of the business. Acuta Capital Partners LLC purchased a new position in shares of Benitec Biopharma in the 3rd quarter valued at approximately $274,000. Ameriprise Financial Inc. lifted its holdings in shares of Benitec Biopharma by 138.4% during the fourth quarter. Ameriprise Financial Inc. now owns 35,476 shares of the biotechnology company’s stock worth $448,000 after purchasing an additional 20,597 shares during the period. 683 Capital Management LLC acquired a new stake in shares of Benitec Biopharma during the fourth quarter worth $452,000. Northern Trust Corp grew its position in Benitec Biopharma by 54.2% in the 4th quarter. Northern Trust Corp now owns 38,200 shares of the biotechnology company’s stock valued at $482,000 after buying an additional 13,425 shares during the last quarter. Finally, MYDA Advisors LLC acquired a new position in Benitec Biopharma in the 4th quarter valued at $632,000. Institutional investors and hedge funds own 52.19% of the company’s stock.

Benitec Biopharma Company Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.